

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in CA/Caplus
NEWS 5 FEB 05 German (DE) application and patent publication number format changes
NEWS 6 MAR 03 MEDLINE and LMEDLINE reloaded
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 03 FRANCEPAT now available on STN
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN
NEWS 10 MAR 29 WPIFV now available on STN
NEWS 11 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12 APR 26 PROMT: New display field available
NEWS 13 APR 26 IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 14 APR 26 LITALERT now available on STN
NEWS 15 APR 27 NLDB: New search and display fields available
NEWS 16 May 10 PROUSDDR now available on STN
NEWS 17 May 19 PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS 18 May 12 EXTEND option available in structure searching
NEWS 19 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 20 May 17 FRFULL now available on STN
NEWS 21 May 27 STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS 22 May 27 New UPM (Update Code Maximum) field for more efficient patent SDIs in Caplus
NEWS 23 May 27 Caplus super roles and document types searchable in REGISTRY
NEWS 24 May 27 Explore APOLLIT with free connect time in June 2004

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:56:40 ON 09 JUN 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:56:55 ON 09 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUN 2004 HIGHEST RN 690625-61-7
 DICTIONARY FILE UPDATES: 7 JUN 2004 HIGHEST RN 690625-61-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

=> s l1

SAMPLE SEARCH INITIATED 10:59:54 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 56 TO ITERATE

100.0% PROCESSED 56 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 672 TO 1568
 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
 FULL SEARCH INITIATED 10:59:58 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 1134 TO ITERATE

100.0% PROCESSED 1134 ITERATIONS 1 ANSWERS
 SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	157.10	157.31

FILE 'HCAPLUS' ENTERED AT 11:00:01 ON 09 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Jun 2004 VOL 140 ISS 24
 FILE LAST UPDATED: 8 Jun 2004 (20040608/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 1 L3

=> d 14, ibib abs hitstr, 1

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN


Full Text Citing References

ACCESSION NUMBER: 1997:457074 HCAPLUS
 DOCUMENT NUMBER: 127:81461
 TITLE: Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors
 INVENTOR(S): Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 PATENT ASSIGNEE(S): Celltech Therapeutics Limited, UK; Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9719065	A1	19970529	WO 1996-GB2854	19961120
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5958935	A	19990928	US 1996-753041	19961119

<u>AU 9676314</u>	A1	19970611	<u>AU 1996-76314</u>	19961120
<u>EP 862560</u>	A1	19980909	<u>EP 1996-939171</u>	19961120
<u>EP 862560</u>	B1	20030402		
R: CH, DE, ES, FR, GB, IT, LI				
<u>ES 2195020</u>	T3	20031201	<u>ES 1996-939171</u>	19961120
<u>US 6235746</u>	B1	20010522	<u>US 1999-249760</u>	19990216
<u>PRIORITY APPLN. INFO.:</u>			<u>GB 1995-23675</u>	A 19951120
			<u>US 1996-753041</u>	A3 19961119
			<u>WO 1996-GB2854</u>	W 19961120

OTHER SOURCE(S): MARPAT 127:81461
GI




AB The title compds. {I; R1 = H, halo, (un)substituted alkyl, etc.; R2, R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = H, alkyl; R5 = H, (un)substituted alkyl, alkenyl, alkynyl; R6 = H, halo, (un)substituted NH2, etc.; X = a direct bond, a linker atom, group; R7 = (un)substituted aliph., cycloaliph., heteroaliph., heterocycloaliph., arom. or heteroarom. group}, selective protein kinase inhibitors, particularly the kinases p56lck, p59fyn, ZAP-70 and protein kinase C, and useful in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role, were prepd. Thus, treatment of 4-[3-(3-phthalimidopropoxy)phenyl]-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine with N2H4.H2O in EtOH afforded I.2HCl [R1 = MeO; R2, R3 = Me; R4-R6 = H; R7 = H2N(CH2)3; X = O] which showed IC50 of 22 nM in the protein kinase assay.

IT 191727-68-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted 2-anilinopyrimidines as protein kinase inhibitors)

RN 191727-68-1 HCAPLUS

CN 3-Pyridinecarboxamide, N-[3-[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



=>

L5 STRUCTURE UPLOADED

```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          14.19      171.50
```

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                                ENTRY      SESSION
CA SUBSCRIBER PRICE                      -0.69      -0.69
```

FILE 'REGISTRY' ENTERED AT 11:02:27 ON 09 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUN 2004 HIGHEST RN 690625-61-7
 DICTIONARY FILE UPDATES: 7 JUN 2004 HIGHEST RN 690625-61-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=>
L6      STRUCTURE UPLOADED
```

```
=> s 16
SAMPLE SEARCH INITIATED 11:02:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 14853 TO ITERATE
```


```
6.7% PROCESSED      1000 ITERATIONS          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   289764 TO 304356
PROJECTED ANSWERS:      14624 TO 18052
```


```
L7      50 SEA SSS SAM L6
```

```
=>
L8      STRUCTURE UPLOADED
```


```
=> d 18
L8 HAS NO ANSWERS
L8      STR
```




19
Page 1-A



Page 1-B



Page 2-A



Page 2-B

VPA 7-2/3/4/5/6 S

NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6

NSPEC IS C AT 7
 NSPEC IS C AT 8
 NSPEC IS C AT 9
 NSPEC IS R AT 10
 NSPEC IS R AT 11
 NSPEC IS R AT 12
 NSPEC IS R AT 13
 NSPEC IS R AT 14
 NSPEC IS R AT 15
 NSPEC IS R AT 16
 NSPEC IS R AT 17
 NSPEC IS R AT 18
 NSPEC IS R AT 19
 NSPEC IS R AT 20
 NSPEC IS R AT 21
 DEFAULT MLEVEL IS ATOM
 MLEVEL IS CLASS AT 7 8 9
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

=> s 18

SAMPLE SEARCH INITIATED 11:03:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 531 TO ITERATE

100.0% PROCESSED 531 ITERATIONS

12 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 9238 TO 12002

PROJECTED ANSWERS: 33 TO 447

L9 12 SEA SSS SAM L8

=> s 18 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 11:03:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 10760 TO ITERATE

100.0% PROCESSED 10760 ITERATIONS

248 ANSWERS

SEARCH TIME: 00.00.01

L10 248 SEA SSS FUL L8

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.84

327.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-0.69

FILE 'HCAPLUS' ENTERED AT 11:03:47 ON 09 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Jun 2004 VOL 140 ISS 24
 FILE LAST UPDATED: 8 Jun 2004 (20040608/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l10

L11 42 L10

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.36	329.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.69

FILE 'REGISTRY' ENTERED AT 11:03:57 ON 09 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUN 2004 HIGHEST RN 690625-61-7
 DICTIONARY FILE UPDATES: 7 JUN 2004 HIGHEST RN 690625-61-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>


=>

L12 STRUCTURE UPLOADED

=> d 112


L12 HAS NO ANSWERS

L12 STR




19


Page 1-A



Page 1-B



Page 2-A



Page 2-B

VPA 7-2/3/4/5/6 S

NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS C	AT	7
NSPEC	IS C	AT	8
NSPEC	IS C	AT	9
NSPEC	IS R	AT	10
NSPEC	IS R	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS C	AT	22
NSPEC	IS C	AT	23

DEFAULT MLEVEL IS ATOM
 MLEVEL IS CLASS AT 7 8 9 22
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

=> s 112

SAMPLE SEARCH INITIATED 11:04:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 322 TO ITERATE

100.0% PROCESSED 322 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5364 TO 7516

PROJECTED ANSWERS: 0 TO 0

L13 0 SEA SSS SAM L12

=> s 112 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
 FULL SEARCH INITIATED 11:04:45 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 6585 TO ITERATE

100.0% PROCESSED 6585 ITERATIONS
 SEARCH TIME: 00.00.01

1 ANSWERS

L14 1 SEA SSS FUL L12

=>
 L15 STRUCTURE UPLOADED

=> s l15
 SAMPLE SEARCH INITIATED 11:05:24 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 322 TO ITERATE

100.0% PROCESSED 322 ITERATIONS
 SEARCH TIME: 00.00.01

5 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 5364 TO 7516
 PROJECTED ANSWERS: 5 TO 234

L16 5 SEA SSS SAM L15

=> s l15 full
 THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
 FULL SEARCH INITIATED 11:05:29 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 6585 TO ITERATE

100.0% PROCESSED 6585 ITERATIONS
 SEARCH TIME: 00.00.01

100 ANSWERS

L17 100 SEA SSS FUL L15

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	311.26	640.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.69

FILE 'HCAPLUS' ENTERED AT 11:05:32 ON 09 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 9 Jun 2004 VOL 140 ISS 24
FILE LAST UPDATED: 8 Jun 2004 (20040608/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 117

L18 23 L17

=> s 118 and schelberger, k?/au

123 SCHELBERGER, K?/AU

L19 0 L18 AND SCHELBERGER, K?/AU

=> s 118 and scherer, m?/au

304 SCHERER, M?/AU

L20 0 L18 AND SCHERER, M?/AU

=> s 118 and eicken, k?/au

171 EICKEN, K?/AU

L21 0 L18 AND EICKEN, K?/AU

=> s 118 and hampel, m?/au

116 HAMPEL, M?/AU

L22 0 L18 AND HAMPEL, M?/AU

=> s 118 and ammermann, e?/au

579 AMMERMAN, E?/AU

L23 0 L18 AND AMMERMAN, E?/AU

=> s 118 and lorenz, g?/au

608 LORENZ, G?/AU

L24 0 L18 AND LORENZ, G?/AU

=> s 118 and strathmann, s?/au

242 STRATHMANN, S?/AU

L25 0 L18 AND STRATHMANN, S?/AU

=> d 118, ibib abs fhitr, 1-23

L18 ANSWER 1 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2003:950057 HCAPLUS

DOCUMENT NUMBER: 140:16647

TITLE: Preparation of 2-aminopyridine-3-carboxamides as remedies for angiogenesis mediated diseases

INVENTOR(S): Askew, Benny; Adams, Jeffrey; Booker, Shon; Chen, Guoqing; Dipietro, Lucian V.; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Handley, Michael; Huang, Qi; Kim, Tae-seong; Li, Aiwen; Nishimura, Nobuko; Nomak, Rana; Patel, Vinod F.; Riahi, Babak; Kim, Joseph L.; Xi, Ning; Yang, Kevin; Yuan, Chester Chenguang

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 252 pp., Cont.-in-part of U.S. Ser. No. 46,681.
CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225106	A1	20031204	US 2002-197974	20020717
US 2003125339	A1	20030703	US 2002-46681	20020110
WO 2004007458	A1	20040122	WO 2003-US22417	20030715

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 US 2002-46681 A2 20020110
 US 2002-197974 A 20020717

OTHER SOURCE(S): MARPAT 140:16647
 GI



AB The title compds. [I; R = (un)substituted 4-pyridyl, 2-pyridyl, 4-pyrimidinyl, 4-quinolyl, etc.; R1 = (un)substituted aryl, cycloalkyl, 5-6 membered heteroaryl, 9-10 membered bicyclic and 11-14 membered tricyclic heterocyclyl], which are effective for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like, were prepd. Thus, the title compd. II was prepd. from 2-aminonicotinic acid, 4-chloroaniline, and 4-pyridinecarboxaldehyde. The compds. I showed inhibition of KDR kinase at < 50 μ M. Many compds. I inhibited VEGF-stimulated HUVEC proliferation at a level below 50 nM. Pharmaceutical compn. comprising the compd. I is claimed.

IT 453563-67-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-aminopyridine-3-carboxamides for treating angiogenesis mediated diseases)

RN 453563-67-2 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[3-(4-


morpholinyl)propyl]amino]-4-pyrimidinyl[methyl]amino] - (9CI) (CA INDEX NAME)



L18 ANSWER 2 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 2003:795094 HCAPLUS
 DOCUMENT NUMBER: 140:42006
 TITLE: QSAR study on antibacterial activity of sulfonamides and derived Mannich bases
 AUTHOR(S): Joshi, Sheela; Khosla, Navita
 CORPORATE SOURCE: Takshila campus, Devi Ahilya Vishwavidyalaya, School of Chemical Sciences, Khandwa Road, (M.P.), Indore, India
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(21), 3747-3751
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



I

AB Synthesis and comparative study on antibacterial activities of sulfonamides and their corresponding Mannich bases, e.g., I, are reported. The compds. were screened for their antibacterial activity against various gram-pos. and gram-neg. bacteria and were analyzed statistically. The results showed that the compds. were active against pathogens and they were nontoxic.


IT 635292-58-9P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn., antibacterial activity, toxicity, and structure-activity

relationship of N-nicotinoylaminobenzamidomethyl sulfonamide via
imidation of N-nicotinoylaminobenzamide followed by addn. of
aminobenzenesulfonamides)

RN 635292-58-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[[[4-[(2-pyrimidinylamino)sulfonyl]phenyl]amino]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citations
References

ACCESSION NUMBER: 2003:551338 HCAPLUS

DOCUMENT NUMBER: 139:111702

TITLE: Compositions and methods using ATP-dependent γ -secretase modulators for prevention and treatment of amyloid- β peptide-related disorders, and screening methods for modulators of A β

INVENTOR(S): Netzer, William J.; Greengard, Paul; Xu, Huaxi

PATENT ASSIGNEE(S): The Rockefeller University, USA

SOURCE: PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057165	A2	20030717	WO 2003-US249	20030106
WO 2003057165	A3	20031113		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004028673 A1 20040212 US 2003-337261 20030106

PRIORITY APPLN. INFO.: US 2002-345009P P 20020104

OTHER SOURCE(S): MARPAT 139:111702

AB The invention provides methods and compns. for modulating levels of amyloid- β peptide (A β) exhibited by cells or tissues. The invention also provides pharmaceutical compns. and methods of screening for compds. that modulate A β levels. The invention also provides modulation of A β levels via selective modulation (e.g., inhibition) of ATP-dependent γ -secretase activity. The invention also provides

methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A β -related disorder, by administering a modulator of γ -secretase, including, but not limited to, a selective inhibitor of ATP-dependent γ -secretase activity or an agent that decreases the formation of active (or optimally active) γ -secretase. The invention also provides the use of inhibitors of ATP-dependent γ -secretase activity to prevent, treat or ameliorate the symptoms of Alzheimer's disease.


IT 560070-07-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ATP-dependent enzyme modulators for prevention and treatment of amyloid- β peptide-related disorders, and screening methods for modulators of A β)

RN 560070-07-7 HCAPLUS

CN 3-Pyridinecarboxamide, N-[3-methyl-4-[[5-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 4 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 2003:409452 HCAPLUS
 DOCUMENT NUMBER: 139:226295
 TITLE: Two distinct phosphorylation pathways have additive effects on Abl family kinase activation
 AUTHOR(S): Tanis, Keith Q.; Veach, Darren; Duewel, Henry S.; Bornmann, William G.; Koleske, Anthony J.
 CORPORATE SOURCE: Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, 06520, USA
 SOURCE: Molecular and Cellular Biology (2003), 23(11), 3884-3896
 CODEN: MCEBD4; ISSN: 0270-7306
 PUBLISHER: American Society for Microbiology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The activities of the related Abl and Arg nonreceptor tyrosine kinases are kept under tight control in cells, but exposure to several different stimuli results in a two- to fivefold stimulation of kinase activity. Following the breakdown of inhibitory intramol. interactions, Abl activation requires phosphorylation on several tyrosine residues, including a tyrosine in its activation loop. These activating phosphorylations have been proposed to occur either through autophosphorylation by Abl in trans or through phosphorylation of Abl by the Src nonreceptor tyrosine kinase. The authors show here that these two pathways mediate phosphorylation at distinct sites in Abl and Arg and have additive effects on Abl and Arg kinase activation. Abl and Arg autophosphorylate at several sites outside the activation loop, leading to 5.2- and 6.2-fold increases in kinase activity, resp. The authors also find that the Src family kinase Hck phosphorylates the Abl and Arg activation loops, leading to an addnl. twofold stimulation of kinase activity. The autoactivation pathway may allow Abl family kinases to

integrate or amplify cues relayed by Src family kinases from cell surface receptors.

IT 309760-28-9, WGB-BC 15


RL: BSU (Biological study, unclassified); NUU (Other use, unclassified);

BIOL (Biological study); USES (Uses)

(inhibitor; drug sensitivities of Abl and Arg kinases)

RN 309760-28-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

37

THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 2003:319721 HCAPLUS

DOCUMENT NUMBER: 138:321292

TITLE: Preparation of 2,4,5-trisubstituted pyrimidines as cyclin dependent kinase inhibitors

INVENTOR(S): Dahmann, Georg; Himmelsbach, Frank; Wittneben, Helmut; Pautsch, Alexander; Prokopowicz, Anthony S.; Krist, Bernd; Schnapp, Gisela; Steegmaier, Martin; Lenter, Martin; Schoop, Andreas; Steurer, Steffen; Spevak, Walter

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International G.m.b.H.

SOURCE: PCT Int. Appl., 278 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003032997	A1	20030424	WO 2002-EP11453	20021014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2003171359 A1 20030911 US 2002-271763 20021016

PRIORITY APPLN. INFO.: US 2001-330145P P 20011017

OTHER SOURCE(S): MARPAT 138:321292

GI




AB Title compds. I [R1 = H, alkyl; R2 = (un)substituted alkyl; R3 = H, alkyl; R4 = (un)substituted alkyl; R5 = halo] and their pharmaceutically acceptable salts were prepd. For example, condensation of thiocyanatopyrimidine II, e.g., prepd. from 3,4-dichloroaniline and 2-chloro-4-thiocyanato-5-nitropyrimidine in one step, and acetylaminomethylamine provided trisubstituted pyrimidine III in 88% yield. In CDK1/CyclinB1 kinase inhibition studies, 88-examples of compds. I exhibited IC₅₀ values more than 100 nM. Compds. I are claimed useful for the treatment of diseases characterized by abnormal cell proliferation.

IT 514841-51-1P, Pyridine-2-carboxylic acid [3-[4-(2-acetylaminomethylamino)-5-trifluoromethylpyrimidin-2-ylamino]phenyl]amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of trisubstituted pyrimidines as cyclin dependent kinase inhibitors)

RN 514841-51-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-[[4-[[2-(acetylaminomethylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]phenyl]-5-(trifluoromethyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER:

2002:889028 HCAPLUS

DOCUMENT NUMBER:

137:379974

TITLE:


Pyridylpyrimidine derivatives as effective compounds against prion diseases

INVENTOR(S):

Stein-Gerlach, Matthias; Salassidis, Konstadinos;

PATENT ASSIGNEE(S): Bacher, Gerald; Mueller, Stefan
 SOURCE: Axxima Pharmaceuticals A.-G., Germany
 PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2002093164</u>	A2	20021121	<u>WO 2002-EP5420</u>	20020516
<u>WO 2002093164</u>	A3	20030904		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
<u>EP 1395261</u>	A2	20040310	<u>EP 2002-769490</u>	20020516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
<u>US 2003176443</u>	A1	20030918	<u>US 2002-204041</u>	20020816
PRIORITY APPLN. INFO.: <u>EP 2001-111858</u> A 20010516 <u>US 2001-293528P</u> P 20010529 <u>EP 2001-117113</u> A 20010713 <u>US 2001-305898P</u> P 20010718 <u>WO 2002-EP5420</u> W 20020516				
OTHER SOURCE(S): MARPAT 137:379974 GI				



AB The present invention relates to pyridylpyrimidine derivs. of the general formula (I) : wherein R represents hydrogen or Me and Z represents nitrogen contg. functional groups, the use of the pyridylpyrimidine derivs. as pharmaceutically active agents, esp. for the prophylaxis and/or treatment of prion infections and prion diseases, as well as compns. contg. at least one pyridylpyrimidine deriv. and/or pharmaceutically

acceptable salt thereof. Furthermore, the present invention is directed to methods for preventing and/or treating prion infections and prion diseases using said pyridylpyrimidine derivs. Human cellular protein kinases, phosphatases and cellular signal transduction mols. are disclosed as targets for detecting, preventing and/or treating prion infections and diseases, esp. BSE, vCJD, or CJD, which can be inhibited by the inventive pyridylpyrimidine derivs.


IT 152459-79-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyridylpyrimidine derivs. as effective compds. against prion diseases)

RN 152459-79-5 HCAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl]-(9CI) (CA INDEX NAME)



L18 ANSWER 7 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 2002:658116 HCAPLUS

DOCUMENT NUMBER: 137:201332

TITLE: Preparation of heterocyclylalkylamine derivatives as remedies for angiogenesis mediated diseases

INVENTOR(S): Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 502 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066470	A1	20020829	WO 2002-US743	20020111
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003125339	A1	20030703	US 2002-46681	20020110
BR 2002006435	A	20030923	BR 2002-6435	20020111
EP 1358184	A1	20031105	EP 2002-717325	20020111

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EE 200300324 A 20031215 EE 2003-324 20020111

NO 2003003181 A 20030911 NO 2003-3181 20030711

PRIORITY APPLN. INFO.:

US 2001-261339P P 20010112

US 2001-323764P P 20010919



US 2002-46681 A 20020110

WO 2002-US743 W 20020111

OTHER SOURCE(S):

MARPAT 137:201332

GI



AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6-membered partially satd. heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10-membered fused partially satd. heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C:ZNR3, C:ZN(R3)R4; Z = O, S; Y = N:CH, NR5(CR6R7), R8N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6-membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10-membered (un)substituted aryl, 5-, or 6-membered (un)substituted heterocyclyl, 9-11 membered (un)substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkylenyl, alkenylenyl, alkynylenyl; R5 = H, alkyl, aralkyl, C6H5; R6, R7 independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkylenyl; etc.] are prepd. and are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes. Thus, the title compd. II was prepd. from Me 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine carboxaldehyde via coupling reaction.


IT 453563-67-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclylalkylamine derivs. as remedies for angiogenesis mediated diseases)

RN 453563-67-2 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full
Text

Citing
References

ACCESSION NUMBER: 2002:628768 HCAPLUS
DOCUMENT NUMBER: 138:130777
TITLE: Synthesis and study of antimicrobial and antiinflammatory activity of 2-substituted nicotinic acid amines
AUTHOR(S): Pavlova, M. V.; Mikhalev, A. I.; Kon'shin, M. E.; Vasil'eva, M. Yu.; Mardanova, L. G.; Odegova, T. F.; Vakhrrin, M. I.
CORPORATE SOURCE: State Pharmaceutical Academy, Perm, Russia
SOURCE: Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2001), 35(12), 664-666
CODEN: PCJOAU; ISSN: 0091-150X
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The compds. 2-(4-sulfamylanilino)nicotinic acid amides were synthesized by heating 2-chloronicotinic acid amides with p-aminosulfanylamides in 50% acetic acid. The desired 2-aryloxynicotinic acid amides were prepd. via interaction of 2-chloronicotinic acid amides with phenols in DMF in the presence of anhyd. potassium carbonate. The antimicrobial and antiinflammatory activity of these synthesized compds. were evaluated. The antiinflammatory effect of these compds. was only slightly lower compared to that of orthophen, and some of the compds. also displayed a weak antimicrobial effect.


IT 491832-87-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and antimicrobial and antiinflammatory activity of 2-substituted nicotinic acid amines)

RN 491832-87-2 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[[[4-[[[4,6-dimethyl-2-pyrimidinyl]amino]sulfonyl]phenyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 2002:90040 HCAPLUS
 DOCUMENT NUMBER: 136:135022
 TITLE: Preparation of heteroaryl- β -alanine derivatives as antiinflammatory agents and α 4 integrin inhibitors
 INVENTOR(S): Konradi, Andrei W.; Pleiss, Michael A.; Thorsett, Eugene D.; Ashwell, Susan; Welmaker, Gregory S.; Kreft, Anthony; Sarantakis, Dimitrios; Dressen, Darren B.; Grant, Francine S.; Semko, Christopher; Xu, Ying-Zi
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; American Home Products Corporation
 SOURCE: PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008222	A2	20020131	WO 2001-US23096	20010720
WO 2002008222	A3	20020613		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002086882	A1	20020704	US 2001-910431	20010719
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2000-220128P P 20000721

OTHER SOURCE(S): MARPAT 136:135022

GI



AB Disclosed are a series of heteroaryl- β -alanine derivs. I wherein R is a carboxylic acid; R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, or R1 and R2, together with the nitrogen atom to which they are attached, are joined to form an optionally substituted heterocyclic ring provided that said substituted alkyl, substituted alkenyl and substituted cycloalkyl do not carry an aryl, substituted aryl, heteroaryl or substituted heteroaryl group; R3 and R4 are independently a hydrogen or a Me group; R5 is independently selected from the group consisting of heteroatom group; n is zero or an integer 1; Alk is a straight or branched alkylene chain; Ar is an optionally substituted arom. or heteroarom. group, as well as their pharmaceutical use as $\alpha_4\beta_7$ Integrin inhibitors for the treatment of inflammatory diseases. Thus, 3-[4-(3,5-dichloropyrid-4-ylcarboxamido)phenyl]-2-(3-chlorophenylamino)propanoic acid was prepd. as α_4 Integrin inhibitor. The preferred compds. of the invention generally have IC50 values in the $\alpha_4\beta_1$ and $\alpha_4\beta_7$ assays of 1 μ M and below. In the other assays featuring α integrins of other subgroups the same compds. had IC50 values of 50 μ M and above thus demonstrating the potency and selectivity of their action against α_4 integrins. Title compds. were prepd. for treating an inflammatory condition in a mammalian patient which condition is mediated by Very Late Antigen 4 (VLA-4). Inflammatory condition is selected from the group consisting of asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury.

IT 263274-54-0P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heteroaryl- β -alanine derivs. as antiinflammatory agents and α_4 integrin inhibitors)

RN 263274-54-0 HCAPLUS

CN L-Phenylalanine, 4-[[[(3,5-dichloro-4-pyridinyl)carbonyl]amino]-N-[4-(trifluoromethyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 10 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------


ACCESSION NUMBER: 2002:90026 HCAPLUS
 DOCUMENT NUMBER: 136:135019
 TITLE: Preparation of 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as antiinflammatory agents and $\alpha 4$ Integrin inhibitors
 INVENTOR(S): Konradi, Andrei W.; Pleiss, Michael A.; Thorsett, Eugene D.; Ashwell, Susan; Welmaker, Gregory S.; Kreft, Anthony; Sarantakis, Dimitrios; Dressen, Darren B.; Grant, Francine S.; Xu, Ying-Zi
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; American Home Products Corporation
 SOURCE: PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008206	A1	20020131	WO 2001-US23073	20010720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: CH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002055509	A1	20020509	US 2001-910685	20010720
US 6689781	B2	20040210		

PRIORITY APPLN. INFO.: US 2000-220134P P 20000721

OTHER SOURCE(S): MARPAT 136:135019

GI



AB 3-Amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivs. I wherein R is a carboxylic acid; R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, or R1 and R2, together with the nitrogen atom to which they are attached, are joined to form an optionally substituted heterocyclic ring provided that said substituted alkyl, substituted alkenyl and substituted cycloalkyl do not carry an aryl, substituted aryl, heteroaryl or substituted heteroaryl group; R_a and R₃ are independently a hydrogen or a Me group; R₄ and R₅ are independently selected from the group consisting of heteroatom group; n is zero or an integer 1; Alk is a straight or branched alkylene chain; Ar is an optionally substituted arom. or heteroarom. group, as well as their pharmaceutical use as $\alpha 4\beta 7$ Integrin inhibitors for the

treatment of inflammatory diseases. Thus, 3-[4-(3,5-dichloropyrid-4-ylcarboxamido)phenyl]-2-(3-chlorophenylamino)propanoic acid was prepd. as $\alpha 4$ Integrin inhibitor. The preferred compds. of the invention generally have IC50 values in the $\alpha 4\beta 1$ and $\alpha 4\beta 7$ assays of 1 μ M and below. In the other assays featuring α integrins of other subgroups the same compds. had IC50 values of 50 μ M and above thus demonstrating the potency and selectivity of their action against $\alpha 4$ integrins. Title compds. were prepd. for treating an inflammatory condition in a mammalian patient which condition is mediated by Very Late Antigen 4 (VLA-4). Inflammatory condition is selected from the group consisting of asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury.

IT 263274-54-0P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminoaminocarbonyloxyphenylpropionic acid derivs. as a integrin inhibitors)

RN 263274-54-0 HCAPLUS

CN L-Phenylalanine, 4-[[[(3,5-dichloro-4-pyridinyl)carbonyl]amino]-N-[4-(trifluoromethyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 2001:283933 HCAPLUS
 DOCUMENT NUMBER: 134:295834
 TITLE: Preparation of 4-anilinopyrimidines as p38 kinase inhibitors
 INVENTOR(S): Cumming, John Graham
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027089	A1	20010419	WO 2000-GB3929	20001010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 2000014596 A 20020611 BR 2000-14596 20001010

EP 1226126 A1 20020731 EP 2000-968084 20001010

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003511442 T2 20030325 JP 2001-530109 20001010

NZ 517572 A 20031128 NZ 2000-517572 20001010

AU 772293 B2 20040422 AU 2000-78042 20001010

ZA 2002001557 A 20030526 ZA 2002-1557 20020225

NO 2002001728 A 20020612 NO 2002-1728 20020412


PRIORITY APPLN. INFO.:

GB 1999-24092 A 19991013

WO 2000-GB3929 W 20001010

OTHER SOURCE(S): MARPAT 134:295834

GI



I

AB The title compds. [I; m = 0-3; R1 = OH, halo, CF3, CN; R3 = H, halo, alkyl; n = 0-2; R2 = OH, halo, CF3, CN; p = 0-4; Q1 = aryl, heteroaryl], useful in the treatment of diseases or medical conditions mediated by cytokines, were prepd. and formulated. E.g., a multi-step synthesis of I [R1 = 2-Cl, 6-(H2NCO); R2 = H; R3 = Me; p = 0; Q1 = 3-fluoro-5-morpholinophenyl] which showed IC50 of 0.03 μ M against p38 α and IC50 of 16 μ M in the Human Whole Blood test, was given.


IT 334893-52-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of 4-anilinopyrimidines as p38 kinase inhibitors)

RN 334893-52-6 HCAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[2-[(3-amino-2-hydroxypropyl)amino]-4-pyrimidinyl]amino]-4-methylphenyl]-2-(4-morpholinyl) - (9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 12 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2000:662669 HCAPLUS
 DOCUMENT NUMBER: 134:14693
 TITLE: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
 AUTHOR(S): Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John
 CORPORATE SOURCE: Laboratories of Molecular Biophysics, The Rockefeller University, New York, NY, 10021, USA
 SOURCE: Science (Washington, D. C.) (2000), 289(5486), 1938-1942
 CODEN: SCIEAS; ISSN: 0036-8075
 PUBLISHER: American Association for the Advancement of Science
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML). A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML. We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571. Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated. The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases. These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.


IT 309760-28-9D, complexes with Abelson tyrosine kinase

RL: PRP (Properties)

(crystal structure of Abelson tyrosine kinase complex with STI-571 variant shows Tyr393 in kinase activation loop is not phosphorylated)

RN 309760-28-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2000:227650 HCAPLUS
 DOCUMENT NUMBER: 132:265501
 TITLE: Phenylalanine derivatives as alpha 4 integrin inhibitors
 INVENTOR(S): Head, John Clifford; Porter, John Robert; Warrellow, Graham John; Archibald, Sarah Catherine; Hutchinson, Brian Woodside
 PATENT ASSIGNEE(S): Celltech Therapeutics Limited, UK
 SOURCE: PCT Int. Appl., 94 pp.
 CODEN: PIXXD2


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018759	A1	20000406	WO 1999-GB3210	19990928
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6348463	B1	20020219	US 1999-406560	19990927
CA 2338442	AA	20000406	CA 1999-2338442	19990928
AU 9961059	A1	20000417	AU 1999-61059	19990928
EP 1117657	A1	20010725	EP 1999-947680	19990928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002525367	T2	20020813	JP 2000-572219	19990928
US 2002028812	A1	20020307	US 2001-927874	20010810
US 6677339	B2	20040113		


PRIORITY APPLN. INFO.:

GB 1998-21061	A	19980928
US 1999-406560	A3	19990927
WO 1999-GB3210	W	19990928

OTHER SOURCE(S): MARPAT 132:265501
 GI



I



II

AB Phenylalanine derivs. I [Ar1 = arom. or heteroarom. group; Alk1 = (un)substituted aliph. or heteroaliph. chain; L1, L2, L3 = a covalent bond or a linker atom or group; Alk2 = alkylene; R is a carboxylic acid or deriv.; Ar2 = (un)substituted arom. or heteroarom. group; R1, R2, R3, R4, R5 = -L2(Alk3)tL3(R7)u; Alk3 = aliph. or heteroaliph. chain; R6, Ra = H, Me; R7 = H, halo, alkyl, OH, SH, NH2, (un)substituted alkoxy, thioalkyl, or aminoalkyl; m, n, p, t = 0, 1; u = 1-3] and their salts, solvates,

hydrates, and N-oxides were prepd. as selective inhibitors of $\alpha 4$ integrins useful for the prophylaxis and treatment of immune or inflammatory disorders. For example, a multi-step synthesis of the title compd. II was given. Compds. I were tested for inhibition of integrin-dependent cell adhesion and generally have IC50 values of $\leq 1 \mu\text{M}$ in $\alpha 4\beta 1$ and $\alpha 4\beta 7$ assays, and IC50 values of $\geq 50 \mu\text{M}$ in assays of other integrins.


IT 263274-54-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylalanine derivs. as alpha 4 integrin inhibitors)

RN 263274-54-0 HCAPLUS

CN L-Phenylalanine, 4-[[[3,5-dichloro-4-pyridinyl)carbonyl]amino]-N-[4-(trifluoromethyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 1997:457074 HCAPLUS
DOCUMENT NUMBER: 127:81461
TITLE: Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors
INVENTOR(S): Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
PATENT ASSIGNEE(S): Celltech Therapeutics Limited, UK; Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9719065	A1	19970529	WO 1996-GB2854	19961120
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5958935	A	19990928	US 1996-753041	19961119


<u>AU 9676314</u>	A1	19970611	<u>AU 1996-76314</u>	19961120
<u>EP 862560</u>	A1	19980909	<u>EP 1996-939171</u>	19961120
<u>EP 862560</u>	B1	20030402		
R: CH, DE, ES, FR, GB, IT, LI				
<u>ES 2195020</u>	T3	20031201	<u>ES 1996-939171</u>	19961120
<u>US 6235746</u>	B1	20010522	<u>US 1999-249760</u>	19990216

PRIORITY APPLN. INFO.:

<u>GB 1995-23675</u>	A	19951120
<u>US 1996-753041</u>	A3	19961119
<u>WO 1996-GB2854</u>	W	19961120

OTHER SOURCE(S): MARPAT 127:81461

GI




AB The title compds. [I; R1 = H, halo, (un)substituted alkyl, etc.; R2, R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = H, alkyl; R5 = H, (un)substituted alkyl, alkenyl, alkynyl; R6 = H, halo, (un)substituted NH2, etc.; X = a direct bond, a linker atom, group; R7 = (un)substituted aliph., cycloaliph., heteroaliph., heterocycloaliph., arom. or heteroarom. group], selective protein kinase inhibitors, particularly the kinases p56lck, p59fyn, ZAP-70 and protein kinase C, and useful in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role, were prepd. Thus, treatment of 4-[3-(3-phthalimidopropoxy)phenyl]-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine with N2H4.H2O in EtOH afforded I.2HCl [R1 = MeO; R2, R3 = Me; R4-R6 = H; R7 = H2N(CH2)3; X = O] which showed IC50 of 22 nM in the protein kinase assay.

IT 191727-68-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted 2-anilinopyrimidines as protein kinase inhibitors)

RN 191727-68-1 HCAPLUS


CN 3-Pyridinecarboxamide, N-[3-[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 15 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 1997:123312 HCAPLUS
 DOCUMENT NUMBER: 126:220297
 TITLE: Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives
 AUTHOR(S): Zimmermann, Jurg; Buchdunger, Elisabeth; Mett, Helmut; Meyer, Thomas; Lydon, Nicholas B.
 CORPORATE SOURCE: Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, Basel, CH-4002, Switz.
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1997), 7(2), 187-192
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Due to its relatively clear etiol., chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase. Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors.
 IT 152459-78-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of phenylaminopyrimidine derivs. as inhibitors of ABL-kinase)
 RN 152459-78-4 HCAPLUS
 CN 2-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 16 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 1996:380210 HCAPLUS
 DOCUMENT NUMBER: 125:114681
 TITLE: Pyrimidine derivatives and processes for the preparation thereof
 INVENTOR(S): Zimmermann, Juerg
 PATENT ASSIGNEE(S): Ciba-Geigy Corporation, USA
 SOURCE: U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 42,322, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5521184	A	19960528	US 1994-234889	19940428
CA 2148477	AA	19950413	CA 1994-2148477	19940921

PRIORITY APPLN. INFO.:

CH 1992-1083
 US 1993-42322
 CH 1993-2966

A 19920403
 B2 19930402
 A 19931001

OTHER SOURCE(S): MARPAT 125:114681
 GI




AB There are described N-phenyl-2-pyrimidine-amine derivs. (I) wherein R1 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted Ph wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen; R2 and R3 are hydrogen or lower alkyl; one or two of R4, R5, R6, R7 are each nitro, fluoro-substituted lower alkoxy or -N(R9)C(:X)(Y)nR10. These compds. can be used, for example, in the therapy of tumoral diseases. Three example formulations are given.

IT 152459-78-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of phenylaminopyrimidine derivs. as antitumor agents)

RN 152459-78-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl]-(9CI) (CA INDEX NAME)



L18 ANSWER 17 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full
Text

Citing
References

ACCESSION NUMBER: 1995:986264 HCAPLUS
 DOCUMENT NUMBER: 124:109609
 TITLE: Synthesis and herbicidal activity of sulfonylureas; SL-950 and its related compounds
 AUTHOR(S): Murai, Shigeo; Haga, Takahiro; Sakashita, Nobuyuki; Nakamura, Yuji; Honda, Chimoto; Honzawa, Shooichi; Kimura, Fumio; Tsujii, Yasuhiro; Nishiyama, Ryuzo
 CORPORATE SOURCE: Cent. Res. Inst., Ishihara Sangyo Kaisha, Ltd., Kusatsu, 525, Japan
 SOURCE: Nippon Noyaku Gakkaishi (1995), 20(4), 453-62
 CODEN: NNGADV; ISSN: 0385-1559
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB As a results of years of studies on pyridylsulfonylureas, novel compds. bearing substituted carbamoyl moiety on the 3-position of the pyridine ring were quite safe for corn (Zea mays). After studying the structure-activity relationships of substituents on the carbamoyl moiety


and the heterocycles attached to the urea bridge, 2-(4,6-dimethoxypyrimidin-2-ylcarbamoylsulfamoyl)-N,N-dimethylnicotinamide, SL-950 (nicosulfuron) was the most effective against both grass weeds including perennial species and broad leaves at 40-80 g a.e./ha. SL-950 is now under development by Ishihara Sangyo Kaisha, Ltd. Four novel routes to the syntheses of the key intermediates, 2-sulfamoyl-N-substituted nicotinamides, were established.

IT 111990-68-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and herbicidal activity of sulfonylureas, SL-950 and its related compds.)

RN 111990-68-2 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)



L18 ANSWER 18 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 1994:107056 HCAPLUS
DOCUMENT NUMBER: 120:107056
TITLE: Preparation of 2-anilinopyrimidines as antiatherosclerotics and neoplasm inhibitors
INVENTOR(S): Zimmermann, Juerg
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 564409	A1	19931006	EP 1993-810219	19930325
EP 564409	B1	20000119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 188964	E	20000215	AT 1993-810219	19930325
ES 2142857	T3	20000501	ES 1993-810219	19930325
PT 564409	T	20000630	PT 1993-810219	19930325
CA 2093203	AA	19931004	CA 1993-2093203	19930401
CA 2093203	C	20021126		
CZ 283944	B6	19980715	CZ 1993-560	19930401
RU 2125992	C1	19990210	RU 1993-5357	19930401
IL 105264	A1	19990411	IL 1993-105264	19930401
SK 280620	B6	20000516	SK 1993-280	19930401
NO 9301283	A	19931004	NO 1993-1283	19930402
ZA 9302397	A	19931004	ZA 1993-2397	19930402

<u>AU 9335694</u>	A1	19931007	<u>AU 1993-35694</u>	19930402
<u>AU 666709</u>	B2	19960222		
<u>CN 1077713</u>	A	19931027	<u>CN 1993-103566</u>	19930402
<u>CN 1043531</u>	B	19990602		
<u>HU 64050</u>	A2	19931129	<u>HU 1993-982</u>	19930402
<u>JP 06087834</u>	A2	19940329	<u>JP 1993-78096</u>	19930405
<u>JP 2706682</u>	B2	19980128		
<u>GR 3032927</u>	T3	20000731	<u>GR 2000-400623</u>	20000310

PRIORITY APPLN. INFO.:


CH 1992-1083

A 19920403

OTHER SOURCE(S):

MARPAT 120:107056

GI




AB Title compds. [I; R1 = pyridyl, 4-pyrazinyl, (acyl)aminophenyl, etc.; R2, R3 = H, alkyl; 1 or 2 of R4-R8 = NO₂, fluoroalkoxy, NR₉C(:X)YnR₁₀ and the others = H, alkyl, alkanoyl, CF₃, etc.; R₉ = H, alkyl; R₁₀ = (cyclo)aliph. group, heterocyclyl, aryl, etc.; X = O, S, NH, etc.; Y = O or NH; n = 0 or 1] were prepd. Thus, 3-(O₂N)C₆H₄NHC(:NH)NH₂ [prepn. from 3-(O₂N)C₆H₄NH₂ given] was cyclocondensed with R₁COCH:CHNMe₂ (R₁ = 3-pyridyl) (prepn. from 3-acetylpyridine given) to give I (R₁ = 3-pyridyl, R₂ = R₃ = R₅-R₈ = H, R₄ = NO₂). I had IC₅₀ of ~0.5 to 5 μM against protein kinase C in vitro.

IT 152459-78-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as antiatherosclerotic and neoplasm inhibitor)

RN 152459-78-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminol]phenyl]-
(9CI) (CA INDEX NAME)

L18 ANSWER 19 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:

1993:2388 HCAPLUS

DOCUMENT NUMBER:

118:2388

TITLE:

Synthesis and quantitative structure-activity relationships of pyridylsulfonyleurea herbicides

AUTHOR(S):

Murai, S.; Nakamura, Y.; Akagi, T.; Sakashita, N.; Haga, T.

CORPORATE SOURCE:

Cent. Res. Inst., Ishihara Sangyo Kaisha, Ltd., Kusatsu, 525, Japan

SOURCE:

ACS Symposium Series (1992), 504 (Synth. Chem. Agrochem. III), 43-55

CODEN: ACSMC8; ISSN: 0097-6156

DOCUMENT TYPE:

Journal

LANGUAGE: English


AB SL-950 (Nicosulfuron, ISO proposed) is a postemergence application herbicide for corn which has a novel type of pyridylsulfonylurea structure. The analogs of SL-950 were synthesized, and their quant. structure activity relationship analyses was carried out to understand the drug-receptor interaction. The QSAR equations obtained indicates that SL-950 is the most effective compd. among those examd.

IT 111990-68-2P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and herbicidal activity of, structure in relation to)

RN 111990-68-2 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)



L18 ANSWER 20 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full
Text

Citing
References

ACCESSION NUMBER: 1991:192389 HCAPLUS
DOCUMENT NUMBER: 114:192389
TITLE: Improved delivery through biological membranes. 46. Synthesis, characterization and in vitro evaluation of various sulfonamide chemical delivery systems
AUTHOR(S): Brewster, Marcus E.; Deyrup, Margaret; Seyda, Kazimierz; Bodor, Nicholas
CORPORATE SOURCE: Coll. Pharm., Univ. Florida, Gainesville, FL, 32610, USA
SOURCE: International Journal of Pharmaceutics (1991), 68(1-3), 215-29
CODEN: IJPHDE; ISSN: 0378-5173
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Dihydropyridine .dblarw. pyridinium salt type chem. delivery systems were prepd. for several sulfonamides found useful in the treatment of cerebral toxoplasmosis. Sulfadiazine, sulfamethoxazole, sulfamerazine, and sulfamethazine were considered and both aniline (N4) and sulfamide (N1) derivatization were performed. The sulfamethoxazole deriv. in which a reduced nicotinamide moiety was attached at the N1 site provided a compd. which rapidly oxidized in various matrixes and was highly lipophilic. In addn., studies in rat brain homogenates illustrated appropriate conversion of the chem. delivery system with ultimate release of the active sulfa drug.


IT 133411-80-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and quaternization of)

RN 133411-80-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- (9CI)





(CA INDEX NAME)



L18 ANSWER 21 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 1990:526025 HCAPLUS
 DOCUMENT NUMBER: 113:126025
 TITLE: Regioselective synthesis and antitumor activity of 8-chloro-5-(p-N-substituted sulfamoylphenyl)aminobenzo[b][1,8]naphthyridines
 AUTHOR(S): Ebeid, Mohamed Y.; Aly, Samir M. El Moghazy; Eissa, Amal A. H.; Osman, Abdel Monem M.
 CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
 SOURCE: Egyptian Journal of Pharmaceutical Sciences (1990), 31(1-4), 515-25
 CODEN: EJPSBZ; ISSN: 0301-5068
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB A series of title compds. (I R = H or substituted heterocyclic) were prepd. by condensation of the acid chloride (II) with appropriate sulfanilamides (III); R = H or substituted heterocyclics and cyclization of the resulting compds. (IV, R = H or substituted heterocyclic) with POCl₃. Alternatively I were prepd. by reacting sulfanilamides III with 5,8-dichlorobenzo[b][1,8]naphthyridine. Some of I exhibited antitumor activity against Ehrlich ascites tumor in vitro, but none was active against P388 lymphocytic leukemia cell at tested concns. Structure-activity relations are discussed.

IT 127924-02-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and antitumor activity of)

RN 127924-02-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[4-[[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




L18 ANSWER 22 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full
Text

Citing
References

ACCESSION NUMBER: 1990:434463 HCAPLUS
 DOCUMENT NUMBER: 113:34463
 TITLE: Synthesis and antiinflammatory activity of some fenamic acid analogs
 AUTHOR(S): Ebeid, Mohamed Y.; Aly, Samir M. El Moghazy; Eissa, Amal A. H.; Monem, Moustafa A.
 CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
 SOURCE: Egyptian Journal of Pharmaceutical Sciences (1990), 31(1-4), 495-503
 CODEN: EJPSBZ; ISSN: 0301-5068
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




I

AB A series of N4-[2-(3-chlorophenylamino)nicotiny]-N'-substituted sulfanilamides (I, R = H, acyl, heterocyclics) were prepd. Their antiinflammatory activities were also evaluated. I (R = 2-pyridinyl) showed antiinflammatory activity comparable to flufenamic acid.

IT 127924-02-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and antiinflammatory activity of, as fenamic acid analog)

RN 127924-02-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[4-[[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 23 OF 23 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 1988:21919 HCAPLUS
 DOCUMENT NUMBER: 108:21919
 TITLE: Preparation of (pyridinylsulfonyl)pyrimidinylureas as herbicides
 INVENTOR(S): Kimura, Fumio; Haga, Takahiro; Sakashita, Nobuyuki; Honda, Chimoto; Murai, Shiego
 PATENT ASSIGNEE(S): Ishihara Sangyo Kaisha, Ltd., USA
 SOURCE: Eur. Pat. Appl., 51 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 232067	A2	19870812	EP 1987-300502	19870121
EP 232067	A3	19880330		
EP 232067	B1	19910306		
EP 232067	B2	19940316		
R: AT, CH, DE, ES, FR, GB, IT, LI, NL				
JP 62178588	A2	19870805	JP 1987-8286	19870119
IN 164880	A	19890624	IN 1987-BO15	19870120
ZA 8700436	A	19870930	ZA 1987-436	19870121
AT 61365	E	19910315	AT 1987-300502	19870121
ES 2064517	T3	19950201	ES 1990-107643	19870121
CN 87100436	A	19870812	CN 1987-100436	19870127
CN 1016661	B	19920520		
BR 8700357	A	19871208	BR 1987-357	19870127
AU 8768136	A1	19870806	AU 1987-68136	19870129
AU 589250	B2	19891005		
HU 43238	A2	19871028	HU 1987-278	19870129
HU 203450	B	19910828		
JP 63146873	A2	19880618	JP 1987-17323	19870129
JP 2567235	B2	19961225		
RO 102426	B1	19920715	RO 1987-135520	19870129
SU 1826860	A3	19930707	SU 1987-4028928	19870129
JP 09012553	A2	19970114	JP 1996-135697	19870129
PL 149173	B1	19900131	PL 1987-263886	19870130
RO 102425	B1	19920801	RO 1988-135519	19881013
RO 102427	B1	19920801	RO 1988-135521	19881013
EP 388994	A1	19900926	EP 1990-107643	19900423
EP 388994	B1	19941005		
R: AT, CH, DE, ES, FR, GB, IT, LI, NL				
RU 2043718	C1	19950920	RU 1991-4895871	19910628
RU 2027715	C1	19950127	RU 1991-5001676	19910928
CN 1062263	A	19920701	CN 1992-100307	19920118

CN 1042690	B	19990331		
CN 1062352	A	19920701	CN 1992-100308	19920118
CN 1032137	B	19960626		
LV 10151	B	19950220	LV 1992-221	19921127
JP 07233163	A2	19950905	JP 1994-295947	19941107
JP 07252227	A2	19951003	JP 1994-296016	19941107
JP 2567353	B2	19961225		
JP 07267928	A2	19951017	JP 1994-295946	19941107
JP 2506063	B2	19960612		

PRIORITY APPLN. INFO.:

JP 1986-19006	19860130
JP 1986-19863	19860131
JP 1986-86847	19860415
JP 1986-178489	19860729
EP 1987-300502	19870121
CN 1987-100436	19870127
JP 1994-296016	19870129

GI




AB The title compds. [I; R1 = (halo)alkyl, (halo)alkoxyalkyl, alkenyl, alkynyl, (halo)alkoxy, (halo)cycloalkyl, (halo)alkoxycarbonyl, Ph, halophenyl; R2 = H, R1; R1R2N = heterocyclyl; X1, X2 = Me, MeO, EtO; Y = halo, (halo)alkyl, (halo)alkoxy, (halo)alkylthio, (halo)alkoxyalkyl; n = 0-2] and their salts were prepd. as herbicides. 2,5-Dichloronicotinic acid was converted to its acid chloride and amidated with Me2NH. The resulting nicotinamide successively was substituted with PhCH2SH, oxidized with Cl, amidated with Me3CNH2, and deprotected with CF3CO2H to give 5-chloro-N,N-dimethyl-2-sulfamoylnicotinamide. The latter was stirred with Ph (4,6-dimethoxy-2-pyrimidinyl)carbamate at room temp. in MeCN contg. 1,8-diazabicyclo[5.4.0]undec-7-ene to give (pyridinylsulfonyl)pyrimidinylurea II. In postemergence tests 1.25 g II/are gave 100% kill of, e.g., Echinochloa crus-galli and Xanthium strumarium with little effect on corn.

IT 111990-68-2P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as herbicide)

RN 111990-68-2 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)



=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	121.20	762.16
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-15.94	-16.63

FILE 'CAOLD' ENTERED AT 11:08:30 ON 09 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 10:56:40 ON 09 JUN 2004)

FILE 'REGISTRY' ENTERED AT 10:56:55 ON 09 JUN 2004

L1 STRUCTURE UPLOADED
 L2 0 S L1
 L3 1 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 11:00:01 ON 09 JUN 2004

L4 1 S L3
 L5 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 11:02:27 ON 09 JUN 2004

L6 STRUCTURE UPLOADED
 L7 50 S L6
 L8 STRUCTURE UPLOADED
 L9 12 S L8
 L10 248 S L8 FULL

FILE 'HCAPLUS' ENTERED AT 11:03:47 ON 09 JUN 2004

L11 42 S L10

FILE 'REGISTRY' ENTERED AT 11:03:57 ON 09 JUN 2004

L12 STRUCTURE UPLOADED
 L13 0 S L12
 L14 1 S L12 FULL
 L15 STRUCTURE UPLOADED
 L16 5 S L15
 L17 100 S L15 FULL

FILE 'HCAPLUS' ENTERED AT 11:05:32 ON 09 JUN 2004

L18 23 S L17
 L19 0 S L18 AND SCHELBERGER, K?/AU
 L20 0 S L18 AND SCHERER, M?/AU
 L21 0 S L18 AND EICKEN, K?/AU
 L22 0 S L18 AND HAMPEL, M?/AU
 L23 0 S L18 AND AMMERMAN, E?/AU
 L24 0 S L18 AND LORENZ, G?/AU
 L25 0 S L18 AND STRATHMANN, S?/AU

FILE 'CAOLD' ENTERED AT 11:08:30 ON 09 JUN 2004

=> s 117

L26 0 L17

=>